每經AI快訊，4月(yue)9日(ri)，濟川藥(yao)業發布年報，2023年公(gong)(gong)(gong)司(si)實現營業收(shou)入96.55億元(yuan)，同(tong)比增(zeng)長(chang)7.32%；歸屬(shu)于上(shang)市(shi)公(gong)(gong)(gong)司(si)股(gu)(gu)東的凈(jing)利潤28.23億元(yuan)，同(tong)比增(zeng)長(chang)30.04%；基本每股(gu)(gu)收(shou)益(yi)3.08元(yuan)。公(gong)(gong)(gong)司(si)擬(ni)向全(quan)體(ti)股(gu)(gu)東每10股(gu)(gu)派發現金紅(hong)利13元(yuan)（含稅）。報告期(qi)內公(gong)(gong)(gong)司(si)的蒲地藍消炎口服(fu)液、小兒豉翹(qiao)清熱顆(ke)粒、黃龍止咳(ke)顆(ke)粒、健胃消食口服(fu)液等產(chan)品銷售收(shou)入持續增(zeng)長(chang)，同(tong)時公(gong)(gong)(gong)司(si)銷售費(fei)用、管理費(fei)用、財務費(fei)用增(zeng)長(chang)得到有效控制。